Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Argenx Se (ARGX)
NASDAQ:ARGX
ARGX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$349.86 - $678.21
Previous CloseN/A
Volume151.62K
Average Volume (3M)265.50K
Market Cap
$39.09B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.36
Next Earnings
Feb 27, 2025EPS Estimate
1.81Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.50
Shares Outstanding60,760,956
10 Day Avg. Volume227,787
30 Day Avg. Volume265,505
Standard Deviation0.11
R-Squared0.07
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)93.03
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$719.38Price Target Upside12.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
---
Argenx Se News
---
Bulls Say, Bears Say
Bulls Say
EarningsARGX reported a strong 4Q24 with $737MM in Vyvgart revenues, surpassing consensus expectations.
Market ExpansionJapan's Ministry of Health, Labour, and Welfare has approved Vyvdura for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP), allowing for patient at-home self-administration, which brings an added layer of convenience for patients.
Pipeline DevelopmentEmpasiprubart development continues to advance with registrational studies in MMN and CIDP, indicating a robust pipeline.
Bears Say
CompetitionVyvgart MG opportunity potentially expanding to ~60,000 TAM by 2030, with management believing seronegative/ocular MG patients should be ~2x current TAM, indicating increasing competition in the market.
Product DevelopmentThe company announced the decision to discontinue development of efgar’ in bullous pemphigoid.
Regulatory ChallengesThe potential approval of the pre-filled syringe could be a key growth driver given the more convenient dosing, but faces regulatory review challenges.
---
Ownership Overview
―
Insiders
19.91% Mutual Funds
21.55% Other Institutional Investors
57.16% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ARGX FAQ
What was Argenx Se’s price range in the past 12 months?
Argenx Se lowest stock price was $349.86 and its highest was $678.21 in the past 12 months.
What is Argenx Se’s market cap?
Argenx Se’s market cap is $39.09B.
When is Argenx Se’s upcoming earnings report date?
Argenx Se’s upcoming earnings report date is Feb 27, 2025 which is in 8 days.
How were Argenx Se’s earnings last quarter?
Argenx Se released its earnings results on Oct 31, 2024. The company reported $1.39 earnings per share for the quarter, beating the consensus estimate of $0.147 by $1.243.
Is Argenx Se overvalued?
According to Wall Street analysts Argenx Se’s price is currently Undervalued.
Does Argenx Se pay dividends?
Argenx Se does not currently pay dividends.
What is Argenx Se’s EPS estimate?
Argenx Se’s EPS estimate is 1.81.
How many shares outstanding does Argenx Se have?
Argenx Se has 60,760,956 shares outstanding.
What happened to Argenx Se’s price movement after its last earnings report?
Argenx Se reported an EPS of $1.39 in its last earnings report, beating expectations of $0.147. Following the earnings report the stock price went up 6.27%.
Which hedge fund is a major shareholder of Argenx Se?
Currently, no hedge funds are holding shares in ARGX
---
Argenx Se Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$719.38 (12.51% Upside)
$719.38 (12.51% Upside)
Blogger Sentiment
Bullish
ARGX Sentiment 80%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.1%
Last 30 Days ▲ 6.6%
Last 30 Days ▲ 6.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
63.83%
12-Months-Change
Fundamentals
Return on Equity
-5.75%
Trailing 12-Months
Asset Growth
50.18%
Trailing 12-Months
Company Description
Argenx Se
argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. Its products include ARGX-113 for the treatment of autoimmune disease myasthenia gravis and ARGX-110 for the treatment of hematological cancer acute myeloid leukemia. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren on April 25, 2008 and is headquartered in Breda, the Netherlands.
---
ARGX Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a strong financial performance with record-breaking revenue growth and successful product launches, particularly in the CIDP segment. However, challenges such as increased operating expenses and the discontinuation of efgartigimod in MN slightly offset the positive aspects. Overall, the company shows strong momentum and a solid financial position.Read More>---
ARGX Stock 12 Month Forecast
Average Price Target
$719.38
▲(12.51% Upside)
Technical Analysis
Alnylam Pharma
―
Biogen
―
Regeneron
―
Vertex Pharmaceuticals
―
Ultragenyx Pharmaceutical
―
Best Analysts Covering ARGX
1 Year
1 Year Success Rate
34/37 ratings generated profit
1 Year Average Return
+41.74%
assigned a buy rating 2 months ago
Copying Derek Archila's trades and holding each position for 1 Year would result in 91.89% of your transactions generating a profit, with an average return of +41.74% per trade.
---